Syngen Biotech Co Ltd (8279):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Syngen Biotech Co Ltd (8279) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12348
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Syngen Biotech Co Ltd (Syngen) is a biotechnology company. The company manufactures and supplies active pharmaceutical ingredients (APIs), biology fermentation products, nutritional ingredients, nutraceutical ingredients, biology agriculture and aquaculture products, and functional food products. Its nutraceutical ingredients include probiotics, medicinal fungi, and entomogenous fungi. Syngen offers mupirocin, an antibiotic against gram-positive and gram-negative bacteria used for the topical treatment of superficial infections such as impetigo; infections due to staphylococci and streptococci, and to control infected eczema, wounds, and burns. The company sells its products throughout Taiwan. Syngen is headquartered in Tainan, Taiwan.

Syngen Biotech Co Ltd (8279) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Syngen Biotech Plans to Raise USD0.7 Million in Public Offering 10
Syngen Biotech Raises USD5.5 Million in Public Offering of Shares 11
Syngen Biotech Raises USD5 million in Public Offering of Shares 12
Syngen Biotech Raises USD1.5 Million in Public Offering of Shares 13
Syngen Biotech Co Ltd – Key Competitors 14
Syngen Biotech Co Ltd – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Syngen Biotech Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Syngen Biotech Plans to Raise USD0.7 Million in Public Offering 10
Syngen Biotech Raises USD5.5 Million in Public Offering of Shares 11
Syngen Biotech Raises USD5 million in Public Offering of Shares 12
Syngen Biotech Raises USD1.5 Million in Public Offering of Shares 13
Syngen Biotech Co Ltd, Key Competitors 14

List of Figures
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Syngen Biotech Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Syngen Biotech Co Ltd (8279):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nigerian National Petroleum Corporation:企業の戦略的SWOT分析
    Nigerian National Petroleum Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Weatherford International Plc (WFT):企業の財務・戦略的SWOT分析
    Weatherford International Plc (WFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Zimmer Biomet Holdings Inc (ZBH)-医療機器分野:企業M&A・提携分析
    Summary Zimmer Biomet Holdings Inc (Zimmer Biomet) is a medical device company with focus on musculoskeletal healthcare. It carries out the design, development, manufacture, and marketing of reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, cr …
  • Rizzani de Eccher S.p.A.:企業の戦略・SWOT・財務情報
    Rizzani de Eccher S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Rizzani de Eccher S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Securitas AB:企業の戦略・SWOT・財務情報
    Securitas AB - Strategy, SWOT and Corporate Finance Report Summary Securitas AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Pharmaceutical Product Development LLC-製薬・医療分野:企業M&A・提携分析
    Summary Pharmaceutical Product Development LLC (PPD) is a contract research organization (CRO), which offers drug discovery, development and lifecycle management services. The company’s service portfolio encompasses early development clinical trial services, drug research and development, regulatory …
  • Republic Airline, Inc.:企業の戦略・SWOT・財務情報
    Republic Airline, Inc. - Strategy, SWOT and Corporate Finance Report Summary Republic Airline, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • PledPharma AB (PLED):企業の財務・戦略的SWOT分析
    Summary PledPharma AB (PledPharma) is a pharmaceutical company that discovers, manufactures, and develops drugs that protect the body against oxidative stress. The company discovers and develops Aladote and PledOx drugs. Its PledOX drug is used to prevent chemotherapy-induced side effects for colore …
  • NuStar Energy L.P.:企業の戦略・SWOT・財務分析
    NuStar Energy L.P. - Strategy, SWOT and Corporate Finance Report Summary NuStar Energy L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Consort Medical plc (CSRT):製薬・医療:M&Aディール及び事業提携情報
    Summary Consort Medical plc (Consort Medical) is a contract development and manufacturing organization (CDMO) with focus on medical device technologies for drug delivery. It develops, manufactures and markets high volume disposable medical devices for drug delivery and point-of-care (POC) diagnostic …
  • Arkansas Children’s Hospital:企業の戦略的SWOT分析
    Arkansas Children's Hospital - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Tikcro Technologies Ltd (TIKRF):企業の財務・戦略的SWOT分析
    Summary Tikcro Technologies Ltd (Tikcro) is a biotechnology company that discovers, develops, manufactures and markets antibodies. The company undertakes clinical trials for its pipeline products PD1, PDL1, PDL2, TIGIT and CTLA-4 products, among others. Tikcro products are based on 3D antigens desig …
  • Energy Resources Conservation and Development Commission:企業の戦略的SWOT分析
    Energy Resources Conservation and Development Commission - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key …
  • Skyworth Digital Holdings Limited:企業の戦略・SWOT・財務情報
    Skyworth Digital Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Skyworth Digital Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Oncolix Inc (ONCX):製薬・医療:M&Aディール及び事業提携情報
    Summary Oncolix Inc (Oncolix) is a clinical stage biotechnology company. It is developing a targeted therapeutic protein, Prolanta for the treatment of ovarian, breast and other cancers. Prolanta is a recombinant analogue to the human prolactin and acts as an antagonist to the prolactin receptor. On …
  • Energy Recovery Inc (ERII):企業の財務・戦略的SWOT分析
    Energy Recovery Inc (ERII) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Aqua Bio Technology ASA (ABT):企業の財務・戦略的SWOT分析
    Summary Aqua Bio Technology ASA (ABT) is a biotechnology company that develops, produces and markets new active ingredients. The company’s products comprise Aquabeautine XL and Smids. Its product Aquabeautine XL is derived from the hatching fluid of salmon. ABT’s products are based on research and d …
  • United Supermarkets LLC:戦略・SWOT・企業財務分析
    United Supermarkets LLC - Strategy, SWOT and Corporate Finance Report Summary United Supermarkets LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • IntriCon Corp (IIN):企業の財務・戦略的SWOT分析
    Summary IntriCon Corp (IntriCon) is a designer, developer and manufacturer of miniature and micro-miniature body-worn medical and electronics products. The company’s products comprise glucose monitoring, medical coils, cardiac monitoring, amplifiers, systems, plastic medical molding, support product …
  • United Networks Ltd (UNL):企業の財務・戦略的SWOT分析
    United Networks Ltd (UNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆